Novartis to probe Indian drug approval allegations
ZURICH (Reuters) - Swiss drugmaker Novartis said on Thursday it would investigate alleged drug approval irregularities in India after a parliamentary report found the country's regulator colluded with pharmaceutical firms to speed up approval procedures.
"We will investigate the allegations presented in the government's report," Novartis said in a statement.
The parliamentary committee reviewed 39 randomly selected drugs approved by the Central Drugs Standard Control Organization (CDSCO).
In the case of 11, including Novartis' everolimus and aliskiren, it found that "mandatory" Phase III trials - the final stage of testing before a drug is approved - had not been conducted as required.
Specifically, in the case of everolimus, the CDSCO relied on the judgment of non-medical staff rather than seeking the opinion of independent experts, the report said.
Novartis said it followed one global ethical standard for conducting clinical trials worldwide and stood behind the safety and efficacy of its products.
- First Ebola victim in Sierra Leone capital on the run
- Former WWE champ nabs suspected burglar in Arizona
- Apple iPhones allow extraction of deep personal data, researcher finds
- EU edges to economic sanctions on Russia but narrows scope |
- China's Guangdong province removes over 850 'naked officials' from their posts
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video